NCT05118841Unknown1 期
A Phase 1, Open-Label, First in Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZX-4081 in Patients With Advanced Solid Tumors
Nanjing Zenshine Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年1月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Determine the recommended Phase 2 dose (RP2D) of ZX-4081
研究概览
简要总结
A Phase 1, first-in-human, open-label, multicenter, dose escalation and dose expansion study to investigate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of ZX-4081 administered orally (PO) twice daily (BID) in 28-day cycles in patients with Advanced Solid Tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic or locally advanced solid tumor malignancies (breast cancer, urothelial cancer, ovarian cancer, melanoma, NSCLC, renal cell carcinoma, squamous cell cancer of the head and neck, colorectal cancer, and hepatocellular carcinoma) that has progressed on, is refractory to, intolerant to, or for which there is no curative standard of care therapy.
- •Measurable disease with at least 1 lesion amenable to response assessment per RECIST 1.
- •Demonstrate adequate organ function. All screening laboratories should be performed within 14 days of treatment initiation.
- •Has a performance status of 0-2 on the ECOG Performance Scale.
- •Life expectancy >12 weeks at baseline.
- •Women of childbearing potential must have negative serum or urine pregnancy test within 72 hours prior to receiving the first study drug administration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Women of childbearing potential must be willing to use an adequate method of contraception from 30 days prior to the first study drug administration and 120 days following last day study drug administration.
- •Male patients of childbearing potential must be surgically sterile, or must agree to use adequate method of contraception during the study and at least 120 days following the last day of study drug administration.
- •Age ≥18 years at screening.
- •Able and willing to provide written informed consent and to follow study instructions.
排除标准
- •Patient has disease that is suitable for therapy administered with curative intent.
- •Untreated or uncontrolled central nervous system (CNS) involvement.
- •Any concurrent or recent use (within 28 days or 5 half-lives, whichever is longer) of chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment.
- •Unresolved toxicities from prior therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, with exception of alopecia and vitiligo.
- •Systemic corticosteroids at doses exceeding 10 mg/day prednisone or equivalent.
- •Patient has an active infection requiring systemic therapy.
- •Patients who have known active HIV, Hepatitis or active COVID-19 infection. (Patients who have been vaccinated against Hepatitis B and who are positive only for the Hepatitis B surface antibody are permitted to participate in the study). Patients who are positive for hepatitis B or C virus must be tested for and have an undetectable viral load.
- •Patients with unstable/inadequate cardiac function:
- •New York Heart Association Class 3 or 4 congestive heart failure,
- •Uncontrolled hypertension,
- •Acute coronary syndrome within 6 months,
- •Clinical important cardiac arrhythmia,
- •A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >470 milliseconds (ms) (CTCAE grade 1) using Fredericia's QT correction formula.
- •A history of additional risk factors for Torsades de Pointes(TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
- •The use of concomitant medications that prolong the QT/QTc interval.
- •Concomitant use or recent use (at least 2 weeks before the start of ZX-4081 treatment) of drugs that are known to be strong CYP3A4/5 inhibitors and CYP3A4/5 inducers (See 5.4.2 for a list of study medications not allowed during this study).
- •Concomitant use of drugs that are sensitive substrates with narrow therapeutic index for one of the following: CYP2C9, CYP2C19, CYP2C8, CYP2D6 and CYP3A4 (See 5.4.2 for a list of study medications not allowed during this study).
- •Concomitant use of drugs that are sensitive substrates with narrow therapeutic index for one of the following transporters: P-glycoprotein (P-gp) and Breast Cancer resistance Protein (BCRP).
- •Recent use a proton pump inhibitor (within 4 days prior to the start ZX-4081 treatment) or a histamine H2 blocker (within 2 days prior to the start of ZX-4081 treatment).
- •Uncontrolled concurrent illness.
- •Patient has concurrent active malignancy other than nonmelanoma skin cancer, carcinoma in situ of the cervix, or superficial bladder cancer who has undergone potentially curative therapy with no evidence of disease. Patients with other previous malignancies are eligible if disease-free for >2 years.
- •Participation in another clinical trial of an investigational agent within 30 days of screening.
- •Patient has known psychiatric, substance abuse or other disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the investigator.
- •Patients who are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 30 days after the last dose of trial treatment.
研究组 & 干预措施
ZX-4081 Dose Level 1
Experimental
Starting dose (SD) of ZX-4081 administered orally twice daily (BID) in a 28-day cycle
干预措施: ZX-4081 (Drug)
ZX-4081 Dose Level 2
Experimental
2-times the SD of ZX-4081 administered orally BID in a 28-day cycle
干预措施: ZX-4081 (Drug)
ZX-4081 Dose Level 3
Experimental
4-times the SD of ZX-4081 administered orally BID in a 28-day cycle
干预措施: ZX-4081 (Drug)
ZX-4081 Dose Level 4
Experimental
6-times the SD of ZX-4081 administered orally BID in a 28-day cycle
干预措施: ZX-4081 (Drug)
ZX-4081 Dose Level 5
Experimental
8-times the SD of ZX-4081 administered orally BID in a 28-day cycle
干预措施: ZX-4081 (Drug)
ZX-4081 Dose Level 6
Experimental
10-times the SD of ZX-4081 administered orally BID in a 28-day cycle
干预措施: ZX-4081 (Drug)
ZX-4081 Expansion Dose Level
Experimental
Recommended Phase 2 Dose (RP2D) (to be determined) of ZX-4081 administered orally BID in a 28-day cycle
干预措施: ZX-4081 (Drug)
结局指标
主要结局
Determine the recommended Phase 2 dose (RP2D) of ZX-4081
时间窗: At the end of Cycle 1 (each cycle is 28 days)
To assess number of patients experiencing dose-limiting toxicities (DLTs) in the dose escalation phase
Safety and tolerability of ZX-4081
时间窗: From first dose of ZX-4081 through 28 days after the last ZX-4081 treatment (up to 2 years); each cycle is 28 days
To examine the incidence of clinical and laboratory adverse events after multiple doses of ZX-4081 in the dose escalation and dose expansion phases
次要结局
- Peak Plasma Concentration of ZX-4081(Days 1, 8, and 15 of Cycle 1 (each cycle is 28 days))
- Area under the plasma concentration of ZX-4081(Days 1, 8, and 15 of Cycle 1 (each cycle is 28 days))
- Half-life of ZX-4081(Days 1, 8, and 15 of Cycle 1 (each cycle is 28 days))
- Peripheral myeloid-derived suppressor cell (MDSC) proportion in the blood(Cycle 1 Day1 , Cycle 2 Day 1, and Cycle 3 Day 1 (each cycle is 28 days))
- Objective response rate (ORR)(Up to 2 years)
- Duration of Response (DOR)(Up to 2 years)
- Overall Survival (OS)(Up to 2 years)
- T cell composition and activation status(Cycle 1 Day1 , Cycle 2 Day 1, and Cycle 3 Day 1 (each cycle is 28 days))
- Progression Free Survival (PFS)(Up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
ALG.APV-527 First-in-human StudySolid TumorNCT05934539Aptevo Therapeutics56
进行中（未招募）
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsLocally Advanced Solid TumorsRecurrent Solid TumorsMetastatic Solid TumorsNCT06031441Genentech, Inc.65
已完成
1 期
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid TumorsSolid Tumor, AdultOvarian Serous AdenocarcinomaBiliary Cancer MetastaticOvarian Serous CystadenocarcinomaPancreatic Ductal AdenocarcinomaNCT05074472ZielBio, Inc.35
招募中
1 期
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid TumorsAdvanced Solid TumorsMetastatic Solid TumorsNCT06770764Trutino Biosciences Inc.50
已完成
1 期
A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid TumorsNeoplasmsNCT02219724Genentech, Inc.174